How much is a BTX stock worth?
One share of BTX stock can currently be purchased for approximately $5.30. How much money does Brooklyn ImmunoTherapeutics make? Brooklyn ImmunoTherapeutics has a market capitalization of $275.83 million.
How often do you update the BTX stock prediction?
"BTX" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "BTX" projections. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Brooklyn ImmunoTherapeutics Inc (BTX).
What is the BTX stock price prognosis for 2026-05-18?
Based on our forecasts, a long-term increase is expected, the "BTX" stock price prognosis for 2026-05-18 is 24.776 USD. With a 5-year investment, the revenue is expected to be around +77.1%. Your current $100 investment may be up to $177.1 in 2026.
Will Brooklyn Immunotherapeutics stock grow/rise/go up?
The Brooklyn ImmunoTherapeutics stock price is 4.890 USD today. Will Brooklyn ImmunoTherapeutics stock price grow / rise / go up? Yes. The BTX stock price can go up from 4.890 USD to 7.221 USD in one year. Is it profitable to invest in Brooklyn ImmunoTherapeutics stock?
WILL BTX stock go back up?
Based on our forecasts, a long-term increase is expected, the "BTX" stock price prognosis for 2027-06-16 is 7.121 USD. With a 5-year investment, the revenue is expected to be around +1424.87%. Your current $100 investment may be up to $1524.87 in 2027.
Should I sell BTX stock?
The consensus among 2 Wall Street analysts covering (NYSEMKT: BTX) stock is to Strong Buy BTX stock.
Is BTX A Good Investment?
Brooklyn Immunotherapeutics Inc (NASDAQ:BTX) The 2 analysts offering 12-month price forecasts for Brooklyn Immunotherapeutics Inc have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +533.03% increase from the last price of 0.55.
Who owns BTX stock?
Top 10 Owners of Brooklyn Immunotherapeutics IncStockholderStakeShares ownedBlackRock Fund Advisors3.30%1,898,020Cypress Point Wealth Management L...3.29%1,887,509Naviter Wealth LLC2.74%1,571,107The Vanguard Group, Inc.2.15%1,236,6056 more rows
What kind of stock is BTX?
Common StockOwnershipTypeCommon Stock HeldCompositionCorporations (Private)8.06MChart Pie chart with 5 slices. View as data table, Chart Created with Highcharts 10.1.0 End of interactive chart.Individuals / Insiders12.34MHedge Fund Managers5.50MPublic and Other17.21M2 more rows
Is Brooklyn Therapeutics a buy?
The 2 analysts offering 12-month price forecasts for Brooklyn Immunotherapeutics Inc have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +420.06% increase from the last price of 0.67.
Should I buy or sell Brooklyn ImmunoTherapeutics stock right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brooklyn ImmunoTherapeutics in the last year. There are currently...
What is Brooklyn ImmunoTherapeutics' stock price forecast for 2022?
1 brokerages have issued twelve-month target prices for Brooklyn ImmunoTherapeutics' shares. Their forecasts range from $3.00 to $9.00. On average,...
Are investors shorting Brooklyn ImmunoTherapeutics?
Brooklyn ImmunoTherapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 2,790,000 s...
When is Brooklyn ImmunoTherapeutics' next earnings date?
Brooklyn ImmunoTherapeutics is scheduled to release its next quarterly earnings announcement on Friday, July 15th 2022. View our earnings forecast...
How were Brooklyn ImmunoTherapeutics' earnings last quarter?
Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) announced its quarterly earnings results on Friday, April, 15th. The company reported ($0.16) earnin...
Who are Brooklyn ImmunoTherapeutics' key executives?
Brooklyn ImmunoTherapeutics' management team includes the following people: Dr. Howard J. Federoff M.D. , Ph.D., CEO, Pres & Director Dr. Monil S...
Who are some of Brooklyn ImmunoTherapeutics' key competitors?
Some companies that are related to Brooklyn ImmunoTherapeutics include ObsEva (OBSV) , OptiNose (OPTN) , Nuvectis Pharma (NVCT) , KemPharm (KMP...
What other stocks do shareholders of Brooklyn ImmunoTherapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Brooklyn ImmunoTherapeutics investors own include Anavex L...
What is Brooklyn ImmunoTherapeutics' stock symbol?
Brooklyn ImmunoTherapeutics trades on the NASDAQ under the ticker symbol "BTX."
Is BTX stock a buy right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Brooklyn ImmunoTherapeutics in the last twelve months. T...
Will Brooklyn ImmunoTherapeutics' stock price go up in 2022?
2 Wall Street analysts have issued twelve-month price targets for Brooklyn ImmunoTherapeutics' stock. Their forecasts range from $5.00 to $9.00. On...
How were Brooklyn ImmunoTherapeutics' earnings last quarter?
Brooklyn ImmunoTherapeutics, Inc. (NYSEAMERICAN:BTX) released its earnings results on Friday, April, 15th. The biotechnology company reported ($0.1...
Who are Brooklyn ImmunoTherapeutics' key executives?
Brooklyn ImmunoTherapeutics' management team includes the following people: Dr. Howard J. Federoff M.D. , Ph.D., CEO, Pres & Director (Age 68, P...
Who are some of Brooklyn ImmunoTherapeutics' key competitors?
Some companies that are related to Brooklyn ImmunoTherapeutics include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) ,...
What other stocks do shareholders of Brooklyn ImmunoTherapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Brooklyn ImmunoTherapeutics investors own include CA (CA)...
What is Brooklyn ImmunoTherapeutics' stock symbol?
Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."
Who are Brooklyn ImmunoTherapeutics' major shareholders?
Brooklyn ImmunoTherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc...
Which institutional investors are selling Brooklyn ImmunoTherapeutics stock?
BTX stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Bank of America Corp DE, Gold...
About Brooklyn ImmunoTherapeutics
Headlines
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.
Brooklyn ImmunoTherapeutics (NYSEAMERICAN:BTX) Frequently Asked Questions
What Kind Of Investors Own Most Of Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX)?
Cypress Point Wealth Management, LLC Buys Brooklyn ImmunoTherapeutics Inc, Robinhood Markets ..
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brooklyn ImmunoTherapeutics in the last year. There are currently 2 buy ratings for the stock.
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors
Investment company Cypress Point Wealth Management, LLC (Current Portfolio) buys Brooklyn ImmunoTherapeutics Inc, Robinhood Markets Inc, Vanguard Ultra-Short Bond ETF, Blend Labs Inc, Upstart Holdings Inc, sells Airbnb Inc, Unity Software Inc, Affirm Holdings Inc, ContextLogic Inc, Matador Resources Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Cypress Point Wealth Management, LLC..
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc.
